KCNV2 retinopathy is an ideal candidate for classical gene replacement therapy utilising AAV, as it is a monogenic disorder which has relatively slow progression [6], caused by a gene that fits within AAV packaging limits. The gene discussed is KCNV2; the disease is retinal disorder.